Annals of Oncology Advance Access originally published online on May 2, 2006
Annals of Oncology 2006 17(7):1072-1082; doi:10.1093/annonc/mdl093
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases
1 Pharmerit, Bethesda, MD; 2 Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA; 3 Clinique de Genolier, 1 route du Muids, 1245 Genolier, Switzerland
* Correspondence to: Mr M. Botteman, Pharmerit, 7272 Wisconsin Avenue, Suite 300, Bethesda, MD 20814, USA. Tel: +1-301-941-1942; E-mail: mbotteman{at}pharmerit.com
Background: Bisphosphonates are recommended to prevent skeletal related events (SREs) in patients with breast cancer and bone metastases (BCBM). However, their clinical and economic profiles vary from one agent to the other.
Materials and methods: Using modeling techniques, we simulated from the perspective of the UK's National Health Service (NHS) the cost and quality adjusted survival (QALY) associated with five commonly-used bisphosphonates or no therapy in this patient population. The simulation followed patients into several health states (i.e. alive or dead, experiencing an SRE or no SRE, and receiving first or second line therapy). Drugs costs, infusion costs, SREs costs, and utility values were estimated from published sources. Utilities were applied to time with and without SREs to capture the impact on quality of life.
Results: Compared to no therapy, all bisphosphonates are either cost saving or highly cost-effective (with a cost per QALY 
£6126). Within this evaluation, zoledronic acid was more effective and less expensive than all other options.
Conclusions: Based on our model, the use of bisphosphonates in breast cancer patients with bone metastases should lead to improved patient outcomes and cost savings to the NHS and possibly other similar entities.
Key words: bone metastases, breast cancer, cost and cost analysis, cost effectiveness
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Dass and P. F.M. Choong Zoledronic acid inhibits osteosarcoma growth in an orthotopic model Mol. Cancer Ther., December 1, 2007; 6(12): 3263 - 3270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss Breast Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1882 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Souberbielle, R Williams, and E McCloskey The cost-effectiveness of bisphosphonates in metastatic breast cancer: letter to the editor in response to Botteman et al. 2006 Ann. Onc., February 1, 2007; 18(2): 393 - 393. [Full Text] [PDF]
|
|